Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Academisch Ziekenhuis Groningen |
| Country | Netherlands |
| Start Date | Jan 01, 2024 |
| End Date | Dec 31, 2027 |
| Duration | 1,460 days |
| Number of Grantees | 19 |
| Roles | Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 101137378 |
Relieving serious health-related suffering for patients in palliative and end-of-life care, be it physical, psychological, social, or spiritual, is a global ethical responsibility.
However, the profound psycho-emotional and existential distress entailed by such suffering, despite often being an enormous burden for both patients and their loved ones, remains a field largely overlooked by health care providers and the scientific community.
Those people may develop mood or anxiety disorder for which neither non-pharmacological nor pharmacological interventions exist. In this context, we believe it is now time to target these unmet needs in the palliative care population.
We want to initiate a paradigm shift at the boundaries between palliative care, psychiatry, psychology, neuroscience, and spiritual care.
Our starting point is the preliminary results being reported for administration of psilocybin, the main psychoactive compound of so-called psychedelic mushrooms, in patients with depression.
The objective of our project is thus to examine the clinical effect of a cutting-edge, individualised and patient-centred, open and standardised Psilocybin Therapy, addressing these unmet needs of patients in palliative care.
We will show high quality evidence via a multi-centre Randomised Clinical Trial of the value of our therapeutic model in patients (and for the following four conditions: COPD, Atypical Parkinsonian Disorders, ALS, and Multiple Sclerosis), their loved ones and care providers, in a diverse sample of the European population, in addition to better understand the mechanisms of therapeutic change of our model.
Finally, our project will establish a sustainable, multi-disciplinary, ecosystem of key European stakeholders jointly contributing to the medical use of psychedelic research and innovation, paving the way towards an ethical and cost-effective deployment of such a new line of care for patients in European palliative care service providers.
Region Hovedstaden; Association Europeenne de Psychiatrie; Stiftelsen 29K Foundation; Narodni Ustav Dusevniho Zdravi; Academisch Ziekenhuis Groningen; Stichting Open: Onderzoek Naar de Psychedelische Ervaring Nederland; Kobenhavns Universitet; Uppsala Universitet; Hk Labs Ab; Stiftelsen Norrsken Mind; European Association for Palliative Care; Universidad de Navarra; European Federation of Neurological Associations; Rijksuniversiteit Groningen; Long Alliantie Nederland; Ctc Clinical Trial Consultants Ab; Centre Expert En Technologies Et Services Pour Le Maintien En Autonomie A Domicile Des Personnes Agees; Fundacao D. Anna de Sommer Champalimaud E Dr. Carlos Montez Champalimaud; Stockholms Universitet
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant